Navigation Links
The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
Date:8/30/2007

LAUSANNE, Switzerland, August 30 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist in oncology and serious medical conditions, today presented the 'Debiopharm Life Sciences Award' to Hungarian scientist Dr Zoltan Nusser for his outstanding research in both fundamental and clinical neuroscience. Funded by Debiopharm and organised by the Ecole Polytechnique Federale de Lausanne (EPFL), the ceremony took place during the EPFL Life Science Symposium 2007. Dr Nusser and his institute received CHF 100'000 and an etched crystal tribute commemorating this honour.

"We were impressed with the quality of research conducted by Dr Nusser," said Rolland-Yves Mauvernay, President of Debiopharm Group. "And more importantly, his work could be applied to drugs that would make a difference to the lives of patients."

"The Debiopharm Life Sciences Award 2007 underscores the spectacular progress we have made in understanding the fundamental mechanisms involved in sensorial perception," added Patrick Aebischer, President of EPFL.

Dr Nusser's work, at the Hungarian Academy of Sciences of Budapest, focuses on understanding the sub cellular organisation and function of synapses in the central nervous system (CNS) and their involvement in neuronal network activities underlying sensory perception. The application of his research could lead to the development of new treatments for patients suffering from CNS diseases. He has received various prizes and has published his research in leading publications including Nature, Neuron and Proceedings of the National Academy of Sciences (PNAS).

About the Debiopharm Life Sciences Award

The Award was set up to mentor and motivate young innovative European researchers in the field of life sciences. Criteria for applications include novelty and originality of the work, as well as its importance and significance in connection with targeted therapeutic fields.

Debiopharm also presents the 'Debiopharm-CCRF China Award' in China; and the 'JCA-Mauvernay Award' in Japan.

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. Debiopharm develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales in excess of $2.6 billion in 2006.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com.

Debiopharm S.A. Contacts

Kim Bill

VP, Business Development &

Licensing

Tel.: +41-(0)21-321-01-11

Fax: +41-(0)21-321-01-69

kbill@debiopharm.com

Additional Media Contacts

In London

Maitland

Brian Hudspith

Tel: +44-(0)20-7379-5151

bhudspith@maitland.co.uk

In New York

Russo Partners, LLC

Wendy Lau

Tel: +1-212-845-4272

Fax: +1-212-845-4260

wendy.lau@russopartnersllc.com


'/>"/>
SOURCE The Debiopharm Group
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Automation of the Eppendorf Perfectprep BAC 96 DNA Kit on the Caliper Life Sciences Sciclone ALH 3000
2. Perscitus Biosciences secures $250K Commerce loan
3. Wisconsin biosciences rise to the challenge
4. Wisconsin professors elected to National Academy of Sciences
5. Quintessence Biosciences advances cancer drug
6. Quintessence Biosciences names new president
7. InvivoSciences receives NIH grant for heart technology
8. Caden Biosciences may signal critical mass
9. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
10. QBI Life Sciences snags $130,000 NIH grant
11. WARF signs licensing pact with BD Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... May 02, 2016 , ... ... clients in mind, the fresh look and added functionality give the agricultural world ... have seen a dynamic shift in agriculture – from precision farming via satellites ...
(Date:5/2/2016)... ... 2016 , ... StarNet Communications Corp, ( http://www.starnet.com/ ) a leading publisher of ... Desktop modules to its flagship X-Win32 PC X server. The new modules enable ... user’s PC over encrypted SSH. , Traditionally, users of PC X servers deploy the ...
(Date:5/2/2016)... ... 02, 2016 , ... F.E.E.D. Co., the Feline Environmental Enrichment ... veterinarian-designed product for indoor cats. The NoBowl Feeding System replaces the bowl with ... way nature intended. NoBowls make cats happy and healthy. , Since being introduced ...
(Date:4/29/2016)... Como, Italy (PRWEB) , ... April 30, 2016 , ... ... their extraordinary textile design, the bioLogic team explored how bacterial properties can be applied ... ways of using Natto bacteria, which move in response to humidity change. The team ...
Breaking Biology Technology:
(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... services, but it also plays a fundamental part in enabling ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/26/2016)... India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a product ... and Onegini today announced a partnership to integrate ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... to provide their customers enhanced security to access ...
Breaking Biology News(10 mins):